Lin Y, Berdeja J, Raje N, et al. First-in-human multicenter study of BB2121 anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma: updated results. EHA 2017, abstract 142.
Allogene anti-CD19 CAR-T-celtherapie voor gerecidiveerde of refractaire B-cel ALL
dec 2022 | Leukemie